GlassScriptPhysician profile
Kathleen Mcbratney
NPI 1063440303
$4,322.96
in general payments reported to CMS, 2019-2025
40 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $627 · 2020: $602 · 2021: $872 · 2022: $793 · 2023: $574 · 2024: $471 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,429.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $636.24 | 2019-2025 | |
| Abbvie INC. | $537.16 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $420.88 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $349.38 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $275.22 | 2021-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $265.53 | 2019-2023 | Breztri |
| Novo Nordisk INC | $246.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $195.67 | 2019-2025 | Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $195.64 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $154.59 | 2019-2022 | |
| Amgen INC. | $119.15 | 2019-2024 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $101.09 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $80.48 | 2020-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.03 | 2021-2023 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $64.11 | 2020-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Mcbratney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.